Cassava Sciences Welcomes Dr. Hulihan as New CMO for Growth

Author: Hannah Lewis Updated: 08-07-2025 07:56 AM

Welcoming Dr. Joseph Hulihan to Cassava Sciences

Cassava Sciences, Inc. has recently appointed Dr. Joseph Hulihan as its new Chief Medical Officer. His significant expertise in clinical development comes at a crucial time for the company, which is dedicated to creating innovative treatments for central nervous system disorders.

Dr. Hulihan's Background and Experience

Dr. Hulihan, who holds a Doctor of Medicine (MD) and a Master of Science in Health Policy, brings more than 25 years of extensive experience in the biotechnology industry. He has a strong track record in developing treatments for epilepsy and other neurological conditions. Before joining Cassava, Dr. Hulihan served as the Chief Medical Officer at Marinus Pharmaceuticals and held senior roles at Janssen Pharmaceuticals, which is part of Johnson & Johnson.

Focus on Tuberous Sclerosis Complex-Related Epilepsy

With the impending clinical study of simufilam—a medication aimed at treating Tuberous Sclerosis Complex (TSC)-related epilepsy—Dr. Hulihan's role is pivotal. His comprehensive knowledge about the TSC community and drug development strategies puts him in a unique position to guide Cassava in its mission. He will spend about half of his time focusing on the clinical development of simufilam.

Excitement for New Opportunities

Expressing his enthusiasm about the new role, Dr. Hulihan stated, "Advancing innovative neurotherapeutics has been the focus of my career, and I look forward to doing so again here at Cassava with simufilam as a potential first-in-class treatment for TSC-related epilepsy." He is particularly eager about initiating a proof-of-concept study in early 2026.

About Cassava Sciences, Inc.

Cassava Sciences, Inc. (NASDAQ: SAVA) is committed to discovering and developing novel therapeutics for serious CNS disorders, including TSC-related epilepsy. The company focuses on simufilam, a proprietary oral small molecule believed to modulate the activity of the filamin A protein, crucial for neuronal development.

Headquartered in Austin, Texas, Cassava continues to push boundaries, committed to transforming the treatment landscape for CNS disorders. Stay tuned as the company embarks on this promising journey under the guidance of Dr. Hulihan.

For More Information

If you're interested in learning more about Cassava Sciences and its innovative developments, please reach out to the following contacts:

Investors
Sandya von der Weid
Email: svonderweid@lifesciadvisors.com

Company Contact
Eric Schoen, Chief Financial Officer
Phone: (512) 501-2450
Email: ESchoen@CassavaSciences.com

Frequently Asked Questions

What role does Dr. Hulihan have at Cassava Sciences?

Dr. Hulihan serves as the Chief Medical Officer and will guide clinical development for simufilam.

What is simufilam?

Simufilam is Cassava's investigational treatment for Tuberous Sclerosis Complex-related epilepsy.

How long has Dr. Hulihan been in the industry?

Dr. Hulihan has over 25 years of experience in clinical development and biotechnology.

Where is Cassava Sciences based?

Cassava Sciences is headquartered in Austin, Texas.

How can investors contact Cassava Sciences?

Investors can reach out via the provided email addresses for inquiries.

About The Author

Hi there, I'm Hannah Lewis, a writer and financial specialist of 36 years old committed to making money understandable and approachable to everyone. Years of working in the field have given me a thorough grasp of market trends, investment techniques, and economic fundamentals. My objective is to enable people, by means of understandable, useful guidance, to take charge of their financial destiny.

I have written many articles for financial blogs over my career that simplify difficult financial ideas into understandable insights. Being financially literate is a critical ability, and I am passionate about enabling people to confidently manage their financial lives. Regardless of your level of experience, my work will help you at every stage of the investment process. I appreciate being allowed to share in your success and financial expansion.

Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.